

# Orthopaedic Working Group Meeting, Malmö January 22-23. January 2017

## **1a, Local treatment of Ewing sarcoma**

(Common session with Oncology)

- Presentation of data on Ewing in pelvis and sacrum, Asle Hesla
- Reflection from London Meeting on "Local Therapy of Ewing Sarcoma", Kjetil Boye
- Should we have a Scandinavian Ewing club?, Antroula Papakonstantinou

*The orthopaedic answer was NO – because we do very well through our internet “meetings”*

## **1 b, Cont. Ortho group with discussing diff Ewing cases:**

- Ewing and other sarcomas in the shoulder, P. Berg
- Ewing sarcoma in the spine (L3), C Trovik
- Ewing sarcoma of the femur, R Löfvenberg

## **2. The diagnostic sarcoma pathway:**

- **What variables** are/should be used in the registration of referrals to a sarcoma center (date of symptom, - referral letter, - reception of letter, - examination, - imaging, - biopsy, -treatment)
- **What are we doing** with all these quality parameters and calculations? ?

*E Styring showed us how these variables are different between our countries and will be discussed further to make our comparisons in treatment and results more accurate!*

- **What are we actually achieving** by making high-priority of the referral pattern in sarcoma suspect diagnosis ?
- Does delay during the diagnostic procedure affect life expectancy?
- Are we fighting tumor biology or for good looking time frames?

*E Styring showed us how both these questions have been answered with yes in several scientific papers!*

### **3. The sarcoma registry:**

- **Is there/should there be** someone who has continuous eye on our common sarcoma registry and makes notice to deviations when comparing the countries?
- **How can we talk about a sarcoma registry** if we are only dealing with the extremities and the trunk wall and not the head and neck, the retroperitoneum, the uterus, the children?

*We had a very interesting view of the annual report to the central register from Sweden, Norway, Denmark and Iceland (ES). Our local registers are actually registering in different ways and with different results. There was a total agreement on viewing first of all so called "orthopaedic sarcomas" in the future. E Styring, O Zaikova, HJjr*

### **4. Our "Sarcoma Homepages" are very different:**

- **In treatment regimes** (diagnostic pathway and follow-up)
- **In information** to patients and families
- **In information** to authorities

*We decided to look through these discrepancies to synchronize our information so the "Google people" will only find total agreement between us.*

### **5. News:**

- **Demonstration on PathFx program and confirmation** on that:

The registry which is by now included in the INCA database is able to receive foreign ID numbers from all over the world. *R Wedin*

- **Increased efficacy of anti-osteoclastic treatment in metastatic bone lesions.** *M Farhang*

*Mehdy recommends using this treatment (Denosunab) especially in painful osteolytic metastatic bone disease and also as a prophylaxis when we expect these bone changes in cancer patients.*

### **6. Reports on cases that have been presented during the last year** in our "Internet Discussion"!

*We find these discussions and our group meetings very fruitful and valuable both for ourselves and in general! We act as are a very strong working team and are able to solve the most complex orthopaedic sarcomas!*